Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody

Yaoxue Xuebao

Volumn 42, Issue 7, 2007, Pages 704-709

  Feng, Yun ^a,b   Zhen, Yong Su ^a   Dai, Yao ^a   Shang, Bo Yang ^a   Zhang, Min ^a   He, Hong Wei ^a   Li, Bao Wei ^a   Shao, Rong Guang ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Immunoconjugate; Lidamycin; Monoclonal antibody; Target therapy; Type IV collagenase

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC C 1027; ANTIBODY CONJUGATE; ANTINEOPLASTIC ANTIBIOTIC; COLLAGENASE; ENEDIYNE; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECT; FIBROSARCOMA; HUMAN; IMMUNOLOGY; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

AMINOGLYCOSIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGENASES; ENEDIYNES; FIBROSARCOMA; HUMANS; IMMUNOCONJUGATES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR BURDEN;

EID: 34548438925     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Lee HJ, Cooperwood JS, You Z, et al. Prodrug and antedrug: two diametrical approaches in designing safer drugs [J]. Arch Pharm Res, 2002, 25:111-136.
2. Francis RJ, Sharma SK, Springer C, et al. A phase 1 trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours [J]. Br J Cancer, 2002, 87:600-607.
3. Shao RG, Zhen YS. Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor anctivity [J]. Acta Pharm Sin, 1995, 30:336-342.
4. Chen Y, Shao R, Bartlam M, et al. Crystallization and preliminary X-ray crystallographic studies of a macromolecular antitumor antibiotic, C1027 [J]. Acta Cryst, 2002, D58:173-175.
5. Wang FQ, Shang BY, Zhen YS. Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11 [J]. Acta Pharm Sin, 2003, 38:515-519.
6. Liu XJ, Jiang M, Liu XY, et al. Antitumor effects of the conjugates of pingyangmycin linked to monoclonal antibody 3D6 and its Fab fragment on hepatoma in mice [J]. Chin J Antibiot, 2002, 27: 496-501.
7. Hamann PR, Hinman LM, Beyer CF, et al. An anti-CD33 antibody- calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker [J]. Bioconjugate Chem, 2002, 13:40-46.
8. Ji YS, He YH, Chen X, et al. Immunotoxins prepared with different coupling methods and their characteristics in vitro and in vivo [J], Prog Biochem Biophys, 1991, 18:443-447.
9. Hamblett KJ, Senter PD, Chace DF, et al. Effects of loading on the antitumor activity of a monoclonal antibody drug conjugate [J]. Clin Cancer Res, 2004, 10:7063-7070.
10. Dai Y, Liu XJ, Zhen YS. Antitumor effect of the novel immunoconjugate compose of pinyangmycin and anti-type collagenase monoclonal antibody [J]. Acta Pharm Sin, 2006, 41:41-46.
11. Zhen YS, Shao RG, Jiang M, et al. Antitumor activity of the conjugates composed of C1027, an anticancer antibiotic, and monoclonal antibody [J]. Chin J Cancer Biother, 1995, 2, 94-98.